Azafaros
5 known investors
Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism. Its lead candidate is being evaluated in a Phase 3 study for treating patients with GM1/GM2 gangliosidoses and related rare lysosomal storage disorders.
BiotechMedical Devices
Investors · 5
Competitors · 1
by search overlapCompanies competing with Azafaros for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Azafaros do?
- Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism. Its lead candidate is being evaluated in a Phase 3 study for treating patients with GM1/GM2 gangliosidoses and related rare lysosomal storage disorders.
- Who are Azafaros's investors?
- Azafaros's investors include BioMedPartners, Forbion, Jeito Capital, Seroba Life Sciences, BioGeneration Ventures.